Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

This study tests a combination of two drugs — obinutuzumab (an antibody that targets cancer cells) and CC-99282 (an immune-modifying pill) — as a first treatment for patients with follicular lymphoma (a slow-growing blood cancer) that has a high tumor burden. **You may be eligible if...** - You are 18 or older with follicular lymphoma (grade 1–3a) that has never been treated - Your lymphoma is at stage II, III, or IV and meets high tumor burden criteria (large lymph nodes, symptoms, bone marrow involvement, or organ compression) - You have adequate organ and blood count function - You are willing to follow strict contraception requirements during and after the study **You may NOT be eligible if...** - You have active lymphoma in the brain or spinal fluid - You have uncontrolled HIV, active hepatitis B or C - You have had significant heart problems (heart attack, serious irregular heartbeat) in the last 6 months - You have a history of blood clots, bleeding disorders, or stroke in the last 6 months - You have previously received CD20 antibody therapy or similar immune-modifying drugs - You have an active autoimmune disease requiring systemic treatment in the last 2 years Talk to your doctor to see if this trial is right for you.